Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 8719638
• 负责人: ROBERT S. DIPAOLA
• 金额: $ 12.5万
• 依托单位: RBHS -CANCER INSTITUTE OF NEW JERSEY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8719638
• 关键词: Animals; Apoptosis; Appointment; Area; Award; Basic Science; Bioinformatics; Bioinformatics Shared Resource; Biology; Biometry; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Institute of New Jersey; Cancer Prevention Intervention; Caring; Cell Separation; Cell Survival; Chemoprevention; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Comprehensive Cancer Center; Computational Biology; Contracts; Data; Dentistry; Development; Discipline; Drug Kinetics; Education and Outreach; Environment; Epidemiology; Etiology; Evaluation; Faculty; Flow Cytometry; Fostering; Foundations; Funding; Genomic Instability; Goals; Grant; Growth; Guidelines; Health Sciences; Histopathology; Hospitals; Housing; Human; Image; Incidence; Institutes; Institution; Instruction; Knockout Mice; Laboratories; Lead; Leadership; Malignant Neoplasms; Medicine; Mission; Monitor; National Cancer Institute; New Jersey; Patient Care; Peer Review; Pharmacodynamics; Pharmacy facility; Physicians; Population; Population Programs; Population Research; Population Sciences; Protocols documentation; Public Health; Publications; Recruitment Activity; Research; Research Personnel; Research Support; Resource Sharing; Resources; Role; Safety; Schools; Science; Scientist; Services; Signal Transduction; Structure; Systems Biology; Therapeutic; Therapeutic Clinical Trial; Time; TimeLine; Training and Education; Transgenic Mice; Translational Research; Translations; Universities; Vision; Wood material; anticancer research; authority; base; biobank; cancer pharmacology; cancer prevention; carcinogenesis; expectation; functional genomics; health science research; improved; innovation; interdisciplinary collaboration; medical schools; meetings; member; metabolomics; mortality; multidisciplinary; neoplasm registry; next generation; novel strategies; oncology; pre-clinical; programs; research and development; success; symposium; tumor growth

PROJECT SUMMARY (See instructions): The Cancer Institute of New Jersey (CINJ) prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated States in our Nation. As a matrix and consortium cancer center that has been continuously funded by the NCI CCSG mechanism since 1997, CINJ conducts state of the art research, patient care, and outreach/education. CINJ is currently comprised of 161 members from a total of 32 academic departments who hold over $92.9 million total peer-reviewed support, $61.1 million annual direct support, $28.9 million total NCI support and $18.7 million annual direct NCI support (a 20% Increase in NCI support since the time ofthe last submission in 2004). Since the appointment of Dr. Robert S. DiPaola as center director in September, 2008, accrual onto investigator initiated therapeutic clinical trials has more than doubled; 17 new faculty were recruited in multiple areas including Basic Science, Clinical Science, Public Health Science, and Systems Biology/Bioinformatics; the Consortium relationship with Princeton University and Rutgers University was strengthened and formalized; the State's cancer registry and SEER contract was moved to CINJ; and an additional four recruitment searches were launched. CINJ now has six established Research Programs: Cell Death and Survival Signaling; Genomic Instability and Tumor Growth; Cancer Pharmacology and Preclinical Therapeutics; Clinical Investigations; Carcinogenesis and Chemoprevention; and Cancer Prevention and Control. CINJ supports 14 Shared Resources, including: Flow Cytometry and Cell Sorting; Functional Genomics; Transgenic and Knockout Mouse; Pharmacokinetics and Pharmacodynamics; Histopathology and Imaging; Biorepository Service; Bioinformatics; Biometrics; Research Pharmacy; Office of Human Research Services; Centralized Education and Training for Clinical Research Personnel; Small Animal Imaging (developing); Metabolomics (developing) and Epidemiology Services (developing). Overall, CINJ has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has State-wide authority beyond the University matrix, thus establishing an environment to foster and formalize a Vision of Transdisciplinary and Translational Research within and beyond the University matrix. We are requesting CCSG support for Senior leadership, Program Leadership, Planning and Evaluation, Developmental Funds, Administration, Shared Resources, Protocol Review and Monitoring, Protocol Specific Research Support, and Data and Safety Monitoring.

项目摘要（参见说明）： 新泽西州癌症研究所 (CINJ) 作为新泽西州唯一的国家癌症研究所 (NCI) 指定的综合癌症中心，能够满足我国最多样化和人口最稠密的州之一的癌症研究需求。作为一个矩阵和联盟癌症中心，自 1997 年以来一直由 NCI CCSG 机制持续资助，CINJ 开展最先进的研究、患者护理和外展/教育。 CINJ 目前由来自 32 个学术部门的 161 名成员组成，他们拥有超过 9,290 万美元的同行评审支持总额、6,110 万美元的年度直接支持、2,890 万美元的 NCI 支持总额和 1,870 万美元的年度直接 NCI 支持（NCI 增加 20%）自 2004 年上次提交以来一直提供支持）。 自 2008 年 9 月任命 Robert S. DiPaola 博士为中心主任以来，研究者发起的治疗性临床试验的应计金额增加了一倍多；基础科学、临床科学、公共卫生科学、系统生物学/生物信息学等多个领域新增17名教师；财团 与普林斯顿大学和罗格斯大学的关系得到加强和正规化；该州的癌症登记处和 SEER 合同已移至 CINJ；并启动了另外四次招聘搜寻工作。 CINJ 目前有六个已建立的研究项目：细胞死亡和生存信号传导；基因组不稳定性与肿瘤 生长;癌症药理学和临床前治疗；临床研究；致癌和化学预防；和癌症预防和控制。 CINJ 支持 14 种共享资源，包括：流式细胞术和细胞分选；功能基因组学；转基因和基因敲除小鼠；药代动力学和 药效学；组织病理学和影像学；生物样本库服务；生物信息学；生物识别；研究药学；人类研究服务办公室；临床研究人员集中教育培训； 小动物成像（开发中）；代谢组学（开发中）和流行病学服务（开发中）。总体而言，CINJ 在 NCI 指定中心中拥有独特的优势，因为它受益于作为矩阵癌症中心的机会，同时拥有大学矩阵之外的全州范围的权威，从而建立了一个环境来培育和正式实现跨学科愿景大学矩阵内外的转化研究。 我们请求 CCSG 在高级领导、项目领导、规划和评估、发展基金、管理、共享资源、方案审查和监测、方案特定研究支持以及数据和安全监测方面提供支持。